Management to outline ‘PolyPid 2030', the Company's long-term vision and pipeline strategy Event to

PolyPid (NASDAQ: PYPD) is approaching a November 28 PDUFA date for D-PLEX100, its lead product candi

PolyPid NASDAQ: PYPD is approaching a November 28 PDUFA date for D-PLEX100, its lead product candida

PolyPid Submitted Marketing Authorization Application to European Medicines Agency for D-PLEX₁₀₀ Las

PETACH TIKVA, Israel, Oct. 01, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or th

PETACH TIKVA, Israel, Sept. 15, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or t

PolyPid Ltd. (PYPD) Q2 2026 Earnings Call Transcript

PolyPid NASDAQ: PYPD said its second-quarter 2026 was marked by the FDA's acceptance of its new drug

PolyPid (NASDAQ:PYPD) reported quarterly losses of $(0.35) per share which beat the analyst consensu

FDA Accepted D-PLEX₁₀₀ NDA with Priority Review; PDUFA Goal Date of November 28, 2026, Approximately

PETACH TIKVA, Israel, July 30, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or th

The FDA did not identify any filing review issues and set a Prescription Drug User Fee Act ("PDU

PDUFA target action date of November 28, 2026, approximately one quarter ahead of Company's previous

Gainers China Pharma Holding (AMEX:CPHI) shares increased by 713.2% to $7.4 during Tuesday's re

HC Wainwright & Co. analyst Brandon Folkes reiterates PolyPid (NASDAQ:PYPD) with a Buy and ma

PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceut

Israeli biotech PolyPid said on Tuesday it had agreed a deal with Azurity Pharmaceuticals ​to commer

PolyPid to potentially receive over $320 million in upfront and milestone payments, including $30 mi

PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceu

If approved, D-PLEX100 would address a critical unmet medical need in the prevention of surgical sit

PETACH TIKVA, Israel, May 20, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the

PolyPid NASDAQ: PYPD said its first quarter marked a transition from late-stage clinical development

PolyPid Ltd. (PYPD) Q1 2026 Earnings Call Transcript

Initiated NDA Submission to the FDA for D-PLEX₁₀₀ ; Completion Expected Imminently  U.S. Commercial

PETACH TIKVA, Israel, May 06, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the

PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceut

PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceut

HC Wainwright & Co. analyst Brandon Folkes reiterates PolyPid (NASDAQ:PYPD) with a Buy and ma

PolyPid (NASDAQ:PYPD) reported quarterly losses of $(0.41) per share which missed the analyst consen

PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma com

Roth Capital analyst Boobalan Pachaiyappan maintains PolyPid (NASDAQ:PYPD) with a Buy and lowers

PolyPid (NASDAQ:PYPD) reported quarterly losses of $(0.37) per share which beat the analyst consensu

PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma comp

Craig-Hallum analyst Chase Knickerbocker maintains PolyPid (NASDAQ:PYPD) with a Buy and lowers th

HC Wainwright & Co. analyst Brandon Folkes reiterates PolyPid (NASDAQ:PYPD) with a Buy and ma

PolyPid (NASDAQ:PYPD) reported quarterly losses of $(0.78) per share which missed the analyst consen

PETACH TIKVA, Israel, July 15, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid&#34

Roth Capital analyst Boobalan Pachaiyappan maintains PolyPid (NASDAQ:PYPD) with a Buy and lowers

JMP Securities analyst Roy Buchanan maintains PolyPid (NASDAQ:PYPD) with a Market Outperform and

The Company Anticipates that with this Additional Funding, PolyPid's Runway would be Extended be

PolyPid's D-PLEX100 met all key endpoints in a Phase 3 trial, showing a 38% drop in infection or